Generation Bio (GBIO) - Market Cap to Earnings
Generation Bio Co. (GBIO) focuses on creating non-viral genetic material delivery methods via innovative lipid particles. This price chart with the -0.60 indicator reflects the price action of the company's asset, whose authority is based on the precision of tools for treating rare pathologies. Unique synthetic patents and colossal bio-manufacturing startup costs ensure a high barrier to entry.
Comprehensive metric breakdowns and analytics for Generation Bio Co (GBIO)
- current price and projected stock value:
- market capitalization indicators:
- book value of equity indicators:
- company liabilities and liquidity data:
Aggregate Debt to Capital Generation Bio Co.|GBIO - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Generation Bio Corp|GBIO - Company Debts|Debts to Book Value Generation Bio Co.|GBIO - Company Long-Term Debt|Company Short-Term Indebtedness Generation Bio|Intermediate Coverage Ratio generationbio.com
- earnings and valuation multiples indicators:
GBIO - Net Profit|Expected Profit Generation Bio Co.|GBIO - P/E Multiple|Market Cap to Projected Earnings Generation Bio Corp|GBIO - Price/Earnings to Growth Ratio|Company Value to EBITDA Generation Bio Co.|GBIO - Operating profit before deduction of amortization|Earnings per share for the trailing year Generation Bio|GBIO - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months generationbio.com|GBIO - Earnings per share growth in current year|Expected net earnings per share growth next year Generation Bio Co.
Comprehensive company analysis:GBIO (generationbio.com)
The lack of commercial revenue at Generation Bio Co. (GBIO) due to the testing stage of its non-viral platforms makes the price-to-earnings dynamics a specific indicator of expectations. The multiple compares market capitalization with net income to measure the investment payback period, which, given negative values, underscores that the company's stability depends on its scientific potential and external financing.
Analysis of competing companies
Price to Earnings Multiple TEM (Tempus AI Inc)|P/E Multiple QGEN|IONS - Market Cap to Earnings|Price to Earnings Ratio Repligen Corp. RGEN|Company Value to Net Income RNA|CRISPR Therapeutics AG - P/E Multiple|WGS - P/E Multiple|RARE (Ultragenyx) - Price to Earnings Ratio|BEAM: Market Price to Net Income Ratio|SRPT (Sarepta Therapeutics Inc) - P/E Multiple|Twist Bioscience Corp (TWST) - Business Payback Period|Price to Earnings Ratio 10x Genomics, Inc. (TXG)|NTLA - Market Cap to Earnings|Price to Earnings Ratio Stoke Therapeutics, Inc. STOK|BLFS: Price to Earnings Multiple|WVE: Price to Earnings Ratio|Company Value to Net Income MAZE (Maze Therapeutics Corp)|SION: P/E Multiple|PRME (primemedicine.com) - Price to Earnings Ratio|TSHA (Taysha Gene Therapies, Inc.) - P/E Multiple|uniQure NV (QURE) - Business Payback Period|Price to Earnings Ratio MeiraGTx PLC (MGTX)|RGNX - Market Cap to Earnings|Solid Biosciences Inc. - Price to Earnings Ratio|Company Value to Net Income OCGN|PacBio - P/E Multiple|Benitec Biopharma Inc (BNTC) - Price to Earnings Ratio|Design Pharma (DSGN) - Price to Earnings Ratio|Market Cap to Earnings Rocket Corp (RCKT)|Price to Earnings Ratio FDMT|Lexeo (LXEO) - Business Payback Period|P/E Multiple KRRO|Editas Medicine Inc (EDIT) - Market Cap to Net Income Ratio|P/E Multiple SLN (Silence Therapeutics Inc.)|ProQR - Price to Earnings Ratio|Codexis Bio - P/E Multiple|Business Payback Period sangamo.com SGMO|nautilus.bio (NAUT) - Price to Earnings Ratio|Market Cap to Earnings Metagenomi Inc. (MGX)|DTIL (Precision BioSciences, Inc.) - P/E Multiple|Price to Earnings Multiple BOLD (Boundless Bio Inc)|Price to Earnings Ratio Exicure, Inc. (XCUR)|imunon.com - Price to Earnings Multiple|P/E Multiple PHIO (Phio Pharmaceuticals Corp.)|P/E Multiple Mustang Bio Inc MBIO|TransCode - P/E Multiple|Market Cap to Net Income Ratio Bionano Genomics, Inc. (BNGO)|APDN: P/E Multiple|Market Cap to Earnings bluebirdbio.com (BLUE)|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd|Price to Earnings Multiple OMGA (Omega Therapeutics Inc)|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Price to Earnings Ratio Syros Pharmaceuticals SYRS|Company Value to Net Income TBIO|TRACON Pharmaceuticals, Inc. - P/E Multiple|UBX - P/E Multiple
